Co-Authors
This is a "connection" page, showing publications co-authored by Reimar Thomsen and Henrik Sørensen.
Connection Strength
2.014
-
Association of a1-Blocker Receipt With 30-Day Mortality and Risk of Intensive Care Unit Admission Among Adults Hospitalized With Influenza or Pneumonia in Denmark. JAMA Netw Open. 2021 02 01; 4(2):e2037053.
Score: 0.927
-
Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2021 04 17; 397(10283):1441-1443.
Score: 0.234
-
SARS-CoV-2 infection and adverse outcomes in users of ACE inhibitors and angiotensin-receptor blockers: a nationwide case-control and cohort analysis. Thorax. 2021 04; 76(4):370-379.
Score: 0.229
-
Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020 10 01; 49(5):1468-1481.
Score: 0.226
-
Renin-Angiotensin System Blockers and Adverse Outcomes of Influenza and Pneumonia: A Danish Cohort Study. J Am Heart Assoc. 2020 10 20; 9(19):e017297.
Score: 0.226
-
Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021 05 05; 373:n1114.
Score: 0.059
-
Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort. Clin Epidemiol. 2020; 12:875-881.
Score: 0.056
-
Association of Nonsteroidal Anti-inflammatory Drug Use and Adverse Outcomes Among Patients Hospitalized With Influenza. JAMA Netw Open. 2020 07 01; 3(7):e2013880.
Score: 0.056